Undergoing both RRM and RRSO was most cost-effective for BRCA1 (RRM at age 30 years; RRSO at age 35 years), BRCA2 (RRM at age 35 years; RRSO at age 40 years), and PALB2 (RRM at age 40 years; RRSO at age 45 years), potentially preventing 464 to 923 OC and BC cases and 130 to 302 deaths per 1000 PV carriers. The gene discussed is PALB2; the disease is breast cancer.